Latest news with #KOLs
Yahoo
23-07-2025
- Business
- Yahoo
IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy
SOUTH SAN FRANCISCO, Calif., July 23, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it will host an in-person and virtual R&D Day on September 8, 2025 from 8:00am to 10:00am ET in New York City to present multiple clinical data updates across the pipeline and highlight the next key drivers of growth and upcoming milestones. "This year marks IDEAYA's ten-year anniversary since our founding, and we look forward to providing multiple clinical data updates across our potential first-in-class pipeline, and highlight our strategic vision, priority areas of scientific focus, and emerging clinical pipeline that will drive the next phase of our growth as a global leader in precision medicine oncology," said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. Speakers will include members of IDEAYA's senior leadership team and key opinion leader(s). Registration for this event can be accessed here or at the investors section of the IDEAYA website at About IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer. Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at a certain investor relation event. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and exchange Commission, including its Annual Report on Form 10-K filed on February 18, 2025. Investor and Media Contact IDEAYA BiosciencesJoshua Bleharski, Financial Officer investor@ View original content to download multimedia: SOURCE IDEAYA Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-07-2025
- Business
- Yahoo
Able View partners with TikTok KOLs to expand distribution
Able View (ABLV) Global has partnered with TikTok key opinion leaders to expand distribution channels. In Able View's continuous efforts to explore new business channels and growth opportunities, the Company has entered into strategic partnerships with multiple prominent TikTok KOLs. These partnerships will promote the distribution of the premium brands represented by the Company through TikTok live-streaming activities . This initiative will further consolidate the business development of the TikTok platform, strengthen the Company's market leadership and core competitiveness, and provide brand partners with optimized marketing solutions and more comprehensive service support. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Disclaimer & DisclosureReport an Issue Sign in to access your portfolio
Associated Press
28-03-2025
- Business
- Associated Press
FLSUN Shines at RAPID+TCT 2025, 10th Anniversary Great Benefit!
From April 8-10, 2025, RAPID+TCT will grandly kick off at Huntington Place in Detroit. FLSUN（Booth 1925）will make a major appearance with its ultra-high-speed 3D printing solutions. DETROIT, March 28, 2025 /PRNewswire/ -- FLSUN has long specialized in delta 3D printing tech. It's dedicated to making ultra-high-speed printers and setting global standards. After years of growth, it's well-regarded in over 150 countries and regions, with its delta models leading the industry in export volume. At this exhibition, FLSUN will showcase its star models, the S1 Pro and T1 Pro with 'Triple speed, Triple Reward'. KOCs and KOLs will present for live streaming, come and join us to win exclusive commemorative gifts. Currently, FLSUN's ultra-high-speed 3D printing technology has been deeply integrated into various fields, and it is the first choice product for more than 100,000 makers, 3D printing entrepreneurs, and 3D printing farmers. In addition, FLSUN has revealed that it will release a new ultra-high-speed personal intelligent manufacturing product in August, continuing the excellent performance of ultra-high-speed printing and unlocking more possibilities for creativity and manufacturing. Stay tuned!
Yahoo
14-03-2025
- Health
- Yahoo
NHS approves long-term daily pill for endometriosis in England
The National Health Service (NHS) in England has approved Gedeon Richter's Ryeqo (relugolix + estradiol + norethisterone), the first long-term pill available for endometriosis, marking a significant breakthrough in treatment. However, it will only be available for patients who have tried all other treatment options. Endometriosis is a chronic condition in which tissue similar to the uterine lining grows outside the uterus, leading to symptoms such as chronic pelvic pain, painful menstruation (dysmenorrhea) and pain during intercourse (dyspareunia). It can also affect fertility. Ryeqo is a combination medication containing relugolix (a gonadotropin-releasing hormone [GnRH] antagonist), estradiol (a form of oestrogen) and norethisterone (a synthetic progestin). Together, these three components help regulate levels of oestrogen and progesterone, which are key hormones involved in endometriosis, effectively reducing symptoms and improving overall disease management. According to key opinion leaders (KOLs) interviewed by GlobalData, injectable treatments for endometriosis often present challenges in patient adherence and comfort. Ryeqo's approval as a standard NHS treatment improves its accessibility, reduces the need for invasive procedures gives patients more control in managing their condition. By eliminating the need for multiple medications and frequent clinic visits for injections, this oral treatment offers a more convenient alternative. Unlike injections, which may initially worsen symptoms, the pill is taken at home and combines all necessary hormones into one convenient tablet. The oral route of administration offers greater clinical control over treatment, as dosages can be adjusted and the medication can be quickly discontinued if necessary. This flexibility provides a significant advantage over long-acting injectable medications, allowing for easier management of side effects and treatment interruptions when needed. Helen Knight, director of medicines evaluation at the UK National Institute for Health and Care Excellence, stated: "This new treatment marks a potential step-change in how we manage endometriosis, putting control back in patients' hands while ensuring value for the taxpayer. The treatment can also be stopped and started more easily, which is particularly important for those planning to have children and for managing side effects. This convenience not only benefits patients but reduces pressure on NHS services." KOLs also highlighted the lack of long-term treatment options for endometriosis, as most available medications are only approved for short-term use. Ryeqo helps address this gap by offering sustained, long-term therapy, providing continuous symptom relief through hormonal regulation. This makes Ryeqo a valuable, non-invasive alternative for patients seeking effective, ongoing management of their condition, ultimately improving their quality of life. The UK joins other nations in expanding access to endometriosis treatment, with this approval offering hope for continued progress in patient care. This approval enhances patients' quality of life while also reducing strain on the NHS by decreasing hospital visits and the need for surgical procedures. Ryeqo's approval brings the UK in line with global advancements in endometriosis treatment, ensuring that women have access to a more effective and convenient option. "NHS approves long-term daily pill for endometriosis in England" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
14-03-2025
- Health
- Yahoo
NHS approves long-term daily pill for endometriosis in England
The National Health Service (NHS) in England has approved Gedeon Richter's Ryeqo (relugolix + estradiol + norethisterone), the first long-term pill available for endometriosis, marking a significant breakthrough in treatment. However, it will only be available for patients who have tried all other treatment options. Endometriosis is a chronic condition in which tissue similar to the uterine lining grows outside the uterus, leading to symptoms such as chronic pelvic pain, painful menstruation (dysmenorrhea) and pain during intercourse (dyspareunia). It can also affect fertility. Ryeqo is a combination medication containing relugolix (a gonadotropin-releasing hormone [GnRH] antagonist), estradiol (a form of oestrogen) and norethisterone (a synthetic progestin). Together, these three components help regulate levels of oestrogen and progesterone, which are key hormones involved in endometriosis, effectively reducing symptoms and improving overall disease management. According to key opinion leaders (KOLs) interviewed by GlobalData, injectable treatments for endometriosis often present challenges in patient adherence and comfort. Ryeqo's approval as a standard NHS treatment improves its accessibility, reduces the need for invasive procedures gives patients more control in managing their condition. By eliminating the need for multiple medications and frequent clinic visits for injections, this oral treatment offers a more convenient alternative. Unlike injections, which may initially worsen symptoms, the pill is taken at home and combines all necessary hormones into one convenient tablet. The oral route of administration offers greater clinical control over treatment, as dosages can be adjusted and the medication can be quickly discontinued if necessary. This flexibility provides a significant advantage over long-acting injectable medications, allowing for easier management of side effects and treatment interruptions when needed. Helen Knight, director of medicines evaluation at the UK National Institute for Health and Care Excellence, stated: "This new treatment marks a potential step-change in how we manage endometriosis, putting control back in patients' hands while ensuring value for the taxpayer. The treatment can also be stopped and started more easily, which is particularly important for those planning to have children and for managing side effects. This convenience not only benefits patients but reduces pressure on NHS services." KOLs also highlighted the lack of long-term treatment options for endometriosis, as most available medications are only approved for short-term use. Ryeqo helps address this gap by offering sustained, long-term therapy, providing continuous symptom relief through hormonal regulation. This makes Ryeqo a valuable, non-invasive alternative for patients seeking effective, ongoing management of their condition, ultimately improving their quality of life. The UK joins other nations in expanding access to endometriosis treatment, with this approval offering hope for continued progress in patient care. This approval enhances patients' quality of life while also reducing strain on the NHS by decreasing hospital visits and the need for surgical procedures. Ryeqo's approval brings the UK in line with global advancements in endometriosis treatment, ensuring that women have access to a more effective and convenient option. "NHS approves long-term daily pill for endometriosis in England" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
